Makito Miyake, Nobutaka Nishimura, Yuki Oda, Tatsuki Miyamoto, Kota Iida, Mitsuru Tomizawa, Takuto Shimizu, Takuya Owari, Kenta Ohnishi, Shunta Hori, et al. Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors. Scientific reports. 2024. 14. 1. 23128-23128
Shunta Hori, Mitsuru Tomizawa, Kuniaki Inoue, Tatsuo Yoneda, Kenta Onishi, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Makito Miyake, Kazumasa Torimoto, et al. Trends in Patient Characteristics on the Japanese Waiting Lists for Deceased-Donor Kidney Transplantation. Are There no Eligibility or Ineligibility Criteria for Registration and Renewal?. Transplantation proceedings. 2024. 56. 8. 1721-1731
Makito Miyake, Satoshi Anai, Yusuke Iemura, Kazuki Ichikawa, Tatsuki Miyamoto, Atsushi Tomioka, Masaomi Kuwada, Yoshitaka Itami, Yukinari Hosokawa, Yoshiaki Matsumura, et al. A Multicenter, Single-Arm, Prospective Trial to Evaluate Efficacy and Safety of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Carboplatin (DD-MVACarbo) Chemotherapy for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer: Study Protocol of the CARBUNCLE Trial. Methods and protocols. 2024. 7. 4
Shunta Hori, Mitsuru Tomizawa, Kuniaki Inoue, Tatsuo Yoneda, Kenta Onishi, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Makito Miyake, Kazumasa Torimoto, et al. Prognostic role of nutritional and inflammatory indicators for patient survival and death with functional graft in living kidney transplant recipients. Clinical and experimental nephrology. 2024
Makito Miyake, Nobutaka Nishimura, Yuki Oda, Tatsuki Miyamoto, Kota Iida, Kuniaki Inoue, Akira Tachibana, Takanosuke Yoshikawa, Keichi Sakamoto, Mikiko Ohnishi, et al. Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort. International journal of clinical oncology. 2024